STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come

STAT PlusBiotech A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come The expected launch of daraxonrasib is likely to deliver both opportunities and challenges Manage alerts for this article Email this article Share this article By Andrew JosephJuly 13, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — When researchers started planning a pancreatic cancer conference here, the aim was to simply offer a counterpart to a regular U.S. meeting, where international scientists and doctors could discuss the latest developments in the specialty. Then came the biggest shake-up in pancreatic cancer care in decades. Advertisement “It’s one of those moments,” Talia Golan, an oncologist at Israel’s Sheba Medical Center, said on a panel that conference organizers hastily added to the schedule centered on a new pancreatic cancer drug. She likened the medicine’s recent clinical trial performance to other milestones in cancer treatment such as the arrival of the first checkpoint inhibitors. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Cancer, drug development, STAT Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter All the health and medical news you need today, in one email Recommended Biotech July 12, 2026 STAT Plus: Tau in the spotlight at Alzheimer’s conference The Readout July 10, 2026 STAT Plus: Roche ends Huntington’s gene-silencing programs Advertisement Biotech July 9, 2026 STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Adam's Biotech Scorecard July 9, 2026 STAT Plus: 931 days. The drug approval scandal hiding in plain sight Subscriber Picks